Histogen (NASDAQ:HSTO) vs. Horizon Therapeutics Public (NASDAQ:HZNP) Head to Head Analysis

Histogen (NASDAQ:HSTO) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Earnings and Valuation

This table compares Histogen and Horizon Therapeutics Public’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Histogen	$19,000.00	152.67	-$10.62 million	($2.92)	-0.23
Horizon Therapeutics Public	$3.63 billion	7.28	$521.48 million	$1.87	61.66

Horizon Therapeutics Public has higher revenue and earnings than Histogen. Histogen is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Histogen has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Profitability

This table compares Histogen and Horizon Therapeutics Public’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Histogen	-63,799.99%	-100.56%	-68.43%
Horizon Therapeutics Public	12.02%	20.46%	11.52%

Institutional & Insider Ownership

3.5% of Histogen shares are held by institutional investors. Comparatively, 80.4% of Horizon Therapeutics Public shares are held by institutional investors. 3.4% of Histogen shares are held by company insiders. Comparatively, 2.2% of Horizon Therapeutics Public shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Histogen and Horizon Therapeutics Public, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Histogen	0	0	0	0	N/A
Horizon Therapeutics Public	0	8	0	0	2.00

Horizon Therapeutics Public has a consensus price target of $110.71, indicating a potential downside of 3.99%. Given Horizon Therapeutics Public’s higher possible upside, analysts clearly believe Horizon Therapeutics Public is more favorable than Histogen.

Summary

Horizon Therapeutics Public beats Histogen on 9 of the 12 factors compared between the two stocks.

About Histogen

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California.

About Horizon Therapeutics Public

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.